Citations

Mayo Clinic

Showing 10 of 108551 citations.

Quantitative CT Texture Analysis of COVID-19 Hospitalized Patients during 3–24-Month Follow-Up and Correlation with Functional Parameters
Volpi, Federica, Colligiani, Leonardo , Chimera, Davide , Tonerini, Michele, Pistelli, Francesco , Pancani, Roberta , Airoldi, Chiara , Bartholmai, Brian J. , Cioni, Dania , Carrozzi, Laura , Neri, Emanuele , Liperi, Annalisa De, Colligiani, Leonardo , Pistelli, Francesco , Pancani, Roberta , Airoldi, Chiara , Bartholmai, Brian J , Cioni, Dania , Neri, Emanuele , Fanni, Salvatore Claudio , Romei, Chiara

Diagnostics | March 5, 2024 | Volume: 14 | Issue: 5 | Pages: 550

10.3390/diagnostics14050550 | PMID 38473022 Get It

Background: To quantitatively evaluate CT lung abnormalities in COVID-19 survivors from the acute phase to 24-month follow-up. Quantitative CT features as predictors of abnormalities’ persistence were investigated. Methods: Patients who survived COVID-19 were retrospectively enrolled and underwent a chest CT at baseline (T0) and 3 months (T3) after discharge, with pulmonary function tests (PFTs). Patients with residual CT abnormalities repeated the CT at 12 (T12) and 24 (T24) months after discharge. A machine-learning-based software, CALIPER, calculated the CT percentage of the whole lung of normal parenchyma, ground glass (GG), reticulation (Ret), and vascular-related structures (VRSs). Differences (Δ) were calculated between time points. Receiver operating characteristic (ROC) curve analyses were performed to test the baseline parameters as predictors of functional impairment at T3 and of the persistence of CT abnormalities at T12. Results: The cohort included 128 patients at T0, 133 at T3, 61 at T12, and 34 at T24. The GG medians were 8.44%, 0.14%, 0.13% and 0.12% at T0, T3, T12 and T24. The Ret medians were 2.79% at T0 and 0.14% at the following time points. All Δ significantly differed from 0, except between T12 and T24. The GG and VRSs at T0 achieved AUCs of 0.73 as predictors of functional impairment, and area under the curves (AUCs) of 0.71 and 0.72 for the persistence of CT abnormalities at T12. Conclusions: CALIPER accurately quantified the CT changes up to the 24-month follow-up. Resolution mostly occurred at T3, and Ret persisting at T12 was almost unchanged at T24. The baseline parameters were good predictors of functional impairment at T3 and of abnormalities’ persistence at T12.
Intrapulmonary Shunting and Paradoxical Air Embolism in Liver Transplantation: A Case Report
Brown, B G, Frasco, Peter E. , Stoker, Alexander D., Brown, Bradly, Brown, Bradly

American Journal of Case Reports | March 5, 2024 | Volume: 25 | Issue: No issue available | Pages: No page available

10.12659/ajcr.943042 | PMID 38627956 Get It

Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts
Asumda, Faizal Z., Campbell, Nellie A. , Hassan, Mohamed A. , Fathi, Reza , Rico, Daniella F. Vasquez, Kiem, Melanie, Vang, Ethan V., Kim, Yo Han , O’Brien, Daniel R. , Buhrow, Sarah A. , Ben-Yair, Vered Katz , Levitt, Mark L. , Leiting, Jennifer L. , Abdelrahman, Amro M. , Zhu, Xinli, Lucien, Fabrice , Truty, Mark J. , Roberts, Lewis R. , O'Brien, Daniel R, Levitt, Mark L , Abdelrahman, Amro M , Lucien, Fabrice , Roberts, Lewis R , Campbell, Nellie A , Luo, Xin , Reid, Joel M. , Moore, Michael J.

Cancers | March 5, 2024 | Volume: 16 | Issue: 5 | Pages: 1050

10.3390/cancers16051050 | PMID 38473407 Get It

Upamostat is an orally available small-molecule serine protease inhibitor that is a highly potent inhibitor of trypsin 1, trypsin 2, trypsin 3 (PRSS1/2/3), and the urokinase-type plasminogen activator (uPA). These enzymes are expressed in many cancers, especially during tissue remodeling and subsequent tumor cell invasion. Opaganib (ABC294640), a novel, orally available small molecule is a selective inhibitor of the phosphorylation of sphingosine to sphingosine-1-phosphate (S-1-P) by sphingosine kinase 2 (SPHK2). Both sphingosine kinase 1 (SPHK1) and SPHK2 are known to regulate the proliferation-inducing compound S-1-P. However, SPHK2 is more critical in cancer pathogenesis. The goal of this project was to investigate the potential antitumor effects of upamostat and opaganib, individually and in combination, on cholangiocarcinoma (CCA) xenografts in nude mice. PAX165, a patient-derived xenograft (PDX) from a surgically resected CCA, expresses substantial levels of SPHK2, PRSS1, PRSS2, and PRSS3. Four groups of 18 mice each were treated with upamostat, opaganib, both, or vehicle. Mouse weights and PAX165 tumor volumes were measured. Tumor volumes in the upamostat, opaganib, and upamostat plus opaganib groups were significantly decreased compared to the control group.
Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer
Upadhyay, Rituraj , Gogineni, Emile , Tocaj, Glenis , Bonomi, Marcelo , Bhateja, Priyanka, Konieczkowski, David J. , Baliga, Sujith , Mitchell, Darrion , Jhawar, Sachin R. , Grecula, J.C., Dibs, Khaled , Gamez, Mauricio E. , Blakaj, Dukagjin , Bonomi, Marcelo , Bhateja, Priyanka , Mitchell, Darrion L , Jhawar, Sachin R , Ma, Sung J., Zhu, Simeng

Cancers | March 5, 2024 | Volume: 16 | Issue: 5 | Pages: 1049

10.3390/cancers16051049 | PMID 38473406 Get It

Objectives: Patients with recurrent and metastatic head and neck cancer (HNC) have limited treatment options. ‘QuadShot’ (QS), a hypofractionated palliative radiotherapy regimen, can provide symptomatic relief and local control and may potentiate the effects of immune checkpoint inhibitors (ICIs). We compared outcomes of QS ± concurrent ICIs in the palliative treatment of HNC. Materials and Methods: We identified patients who received ≥three cycles of QS from 2017 to 2022 and excluded patients without post-treatment clinical evaluation or imaging. Outcomes for patients who received QS alone were compared to those treated with ICI concurrent with QS, defined as receipt of ICI within 4 weeks of QS. Results: Seventy patients were included, of whom 57% received concurrent ICI. Median age was 65.5 years (interquartile range [IQR]: 57.9–77.8), and 50% patients had received prior radiation to a median dose of 66 Gy (IQR: 60–70). Median follow-up was 8.8 months. Local control was significantly higher with concurrent ICIs (12-month: 85% vs. 63%, p = 0.038). Distant control (12-month: 56% vs. 63%, p = 0.629) and median overall survival (9.0 vs. 10.0 months, p = 0.850) were similar between the two groups. On multivariable analysis, concurrent ICI was a significant predictor of local control (HR for local failure: 0.238; 95% CI: 0.073–0.778; p = 0.018). Overall, 23% patients experienced grade 3 toxicities, which was similar between the two groups. Conclusions: The combination of QS with concurrent ICIs was well tolerated and significantly improved local control compared to QS alone. The median OS of 9.4 months compares favorably to historical controls for patients with HNC treated with QS. This approach represents a promising treatment option for patients with HNC unsuited for curative-intent treatment and warrants prospective evaluation.
Effect of Long-Term Tafamidis Treatment on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy
Grogan, Martha , Davis, Margot K. , Sultan, Marla B. , Gundapaneni, Balarama, Angeli, Franca S., Hanna, Mazen , Crespo‐Leiro, María G.

European Journal of Heart Failure | March 5, 2024 | Volume: 26 | Issue: 3 | Pages: 612-615

10.1002/ejhf.3190 | PMID 38439606 Get It

Abstract Aims To evaluate the effect of long-term tafamidis treatment on health-related quality of life (HRQoL) in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) enrolled in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension (LTE) study. Methods and results We examined change from baseline in Kansas City Cardiomyopathy Questionnaire overall summary (KCCQ-OS) and clinical summary (KCCQ-CS) scores in patients who received tafamidis meglumine 80 mg for 30 months in ATTR-ACT and tafamidis (meglumine 80 mg or bioequivalent free acid 61 mg) for 30 months in the LTE study, and in patients who received placebo for 30 months in ATTR-ACT and tafamidis for 30 months in the LTE study. In ATTR-ACT, 176 and 177 patients were randomized to tafamidis 80 mg and placebo, respectively. Patients who continuously received tafamidis had a 6- to 7-point reduction in least squares (LS) mean (standard error) KCCQ-OS and KCCQ-CS scores at month 30 (−6.25 [1.53] and −7.48 [1.39]), with little or no further decline over the next 30 months (−5.92 [1.77] and −9.21 [1.88] at month 60). Patients who received placebo in ATTR-ACT had a 20-point reduction in LS mean KCCQ-OS and KCCQ-CS scores at month 30 (−19.60 [1.94] and −19.90 [2.01]), but the decline slowed after initiating tafamidis (−24.70 [3.04] and −25.30 [3.36] at month 60). Conclusion Tafamidis reduced HRQoL decline in patients with ATTR-CM. Patients continuously treated with tafamidis for 60 months demonstrated stabilized HRQoL. In patients who initially received placebo in ATTR-ACT, tafamidis reduced the decline in HRQoL during the LTE study.
Analysis of editor in chief gender and associated journal variables among 126 pathology journals
Wang, Dayle K. , Clark, Landon M. , Adkins, Brian D. , Khan, Shazia S , Booth, Garrett S. , Jacobs, Jeremy W. , Adkins, Brian David , Booth, Garrett , Jacobs, Jeremy W , Stephens, Laura D.

American Journal of Clinical Pathology | March 4, 2024 | Volume: 162 | Issue: 1 | Pages: 12-16

10.1093/ajcp/aqae018 | PMID 38437878 Get It

Abstract Objectives Gender equity studies have shown that women are underrepresented in journal editor in chief positions, which confer major professional opportunities and influence. We sought to systematically investigate editor in chief gender and journal attributes within pathology. Methods We constructed a journal data set using the Scimago Journal & Country Rank and Clarivate Journal Citation Reports databases. We also included official journals of the major medical societies for the 12 pathology subspecialties recognized by the Association of American Medical Colleges. The final data set included 126 journals. We obtained editor in chief gender, impact factor, publication model (ie, hybrid access vs open access), year of founding, and geographic location for all included pathology journals. Results Women made up only 18% of the 141 total editor in chief positions. This inequity was present irrespective of all pathology journal variables studied. Among 10 journals with 2 editor in chief positions, 5 had only men and 5 had 1 man and 1 woman. All 3 journals with 3 editor in chief positions had 2 men and 1 woman. Conclusions Women are significantly underrepresented among editor in chiefs across pathology journals. Journals and affiliated members should advocate for diversity among these influential positions, given their impact on research, science, and medicine.
Equitable Interoperability Through Precise Control of Sensitive Health Information: An Emerging Pathway to Health Equity
Petersen, Carolyn , Galvin, Hannah K. , Lehmann, Christoph U. , Sharko, Marianne , Lehmann, Christoph U , Petersen, Carolyn

Annals of Internal Medicine | March 4, 2024 | Volume: 177 | Issue: 3 | Pages: 387-388

10.7326/m23-2876 | PMID 38437704 Get It

Abstract P06: Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma
Shivaram, Suganti, Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Qin, Guyu , Anderson, Emilie, Bolarinwa, Abiola , Zepeda‐Mendoza, Cinthya , Dasari, Surendra , Kourelis, Taxiarchis , Kumar, Shaji , Bolarinwa, Abiola B , Tang, Hongwei, Sharma, Neeraj , Lehman, Stacey L. , Gomez, Felicia , Mitra, Amit , Baughn, Linda B.

Blood Cancer Discovery | March 4, 2024 | Volume: 5 | Issue: 2_Supplement | Pages: P06-P06

10.1158/2643-3249.bcdsymp24-p06 Get It

Abstract Multiple myeloma (MM) is the most common blood cancer in African American (AA) individuals. AAs have an increased risk of developing Monoclonal Gammopathy of Undetermined Significance (MGUS) and MM compared to non-Hispanic White (NHW) individuals. While several studies have shown a pivotal role for the immune tumor microenvironment (iTME) in MM pathogenesis, the composition of the iTME in AAs with MM is under investigated. Viably frozen whole bone marrow (BM) aspirates from 128 individuals (53 AA and 75 NHW) with either MM (n=65), MGUS (n=28), smoldering MM (SMM, n=13), or healthy controls (n=22) were evaluated by single cell RNA-sequencing (scRNA-seq) or mass cytometry (CyTOF). We characterized 34 (14 AA and 20 NHW) by scRNA-seq and 94 (39 AA and 55 NHW) by CyTOF. CyTOF samples were stained with Maxpar Direct Immune Profiling Assay Kit (Fluidigm), acquired on a Helios mass cytometer and analyzed in Cytobank. Data were analyzed by logistic equivalent regression model with p<0.05 for significance. ScRNA-seq samples were processed as in Yao, 2022. Data were normalized using scvi-tools and clustered by Uniform manifold approximation and projection (UMAP). Differentially expressed markers between clusters were identified using Model-based Analysis of Single-cell Transcriptomics (MAST) in Seurat R package at FDR < 0.05 and log2 fold change > 0.55. ScRNA-seq of the CD45+ non-tumor lymphocytes revealed 17 immune populations (HSC, erythroblast, MDSC, GMP, CD1c+ DC, CD4+ and CD8+ T cell, CD14+ M1 macrophage, CD16+monocyte, monocyte, pDC, naïve B, pre-B, pro-B, memory B, NK/MAIT). CD3E/D+cells were clustered into naïve/central memory (CCR7+, LEF1+, SELL+), memory (GZMK+), effector (GZMB+, GZMH+, FGFBP2+), g/d (TRDC+), MAIT (SLC4A10+, KLRB1+) and IFN CD8+ T cells (IFIT1+, IFIT2+,IFIT3+). Disease progression was associated with increases in median CD4+ and CD8+ GZMK+ T cells, memory B cells and a reduction in all monocyte clusters. Within the diseased cohort in comparison to NHW patients, AA patients had increased CD3+ T cells (CD4 and CD8+) (AA 57.5% vs. NHW 44.3%) and a reduction in overall monocytes (AA 10.5% vs. 26.5%). These results were validated by CyTOF, which confirmed an increase in CD3+ T cells (AA 53.7% vs. NHW 35.7%, p<0.001) including increases in CD8+ (AA 7.0% vs. NHW 3.2%, p<0.05) and CD4+ terminal effector T cells (AA 5.7% vs. NHW 2.7%, p<0.05) and a reduction in monocytes (AA 18.3% vs. NHW 26.6%) among AAs. After adjusting for age and sex, AAs retained an increase in T cells (OR 1.59 (95%CI 1.2-2.01, p=0.00023)) and a reduction in monocytes (OR 0.88 (95%CI 0.78-1, p=0.045)). Despite the increase in CD8+ T cells in AA patients, we identified reduced GZMK+ T cells and reductions in exhaustion markers (TIGIT, LAG3, TOX) in CD8+ T cells in comparison to NHWs. Nevertheless, the distribution of the immune populations was similar between healthy AA and NHW individuals. Our multiomics approach to characterize the iTME identified significant differences among AA compared to NHW patients with MM. Citation Format: Suganti Shivaram, Hongwei Tang, Huihuang Yan, Shulan Tian, Guyu Qin, Emilie Anderson, Neeraj Sharma, Abiola Bolarinwa, Cinthya Zepeda-Mendoza, Stacey Lehman, Felicia Gomez, Amit Mitra, Surendra Dasari, Taxiarchis Kourelis, Shaji Kumar, Linda Baughn. Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma [abstract]. In: Proceedings of the Blood Cancer Discovery Symposium; 2024 Mar 4-6; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(2_Suppl):Abstract nr P06.
Novel radiotherapeutic strategies in the management of brain metastases: Challenging the dogma
Perlow, Haley K. , Lehrer, Eric J. , Wardak, Zabi , Soliman, Hany , Palmer, Joshua D , Perlow, Haley K , Palmer, Joshua D.

Neuro-Oncology | March 4, 2024 | Volume: 26 | Issue: Supplement_1 | Pages: S46-S55

10.1093/neuonc/noad260 | PMID 38437668 Get It

Abstract The role of radiation therapy in the management of brain metastasis is evolving. Advancements in machine learning techniques have improved our ability to both detect brain metastasis and our ability to contour substructures of the brain as critical organs at risk. Advanced imaging with PET tracers and magnetic resonance imaging-based artificial intelligence models can now predict tumor control and differentiate tumor progression from radiation necrosis. These advancements will help to optimize dose and fractionation for each patient’s lesion based on tumor size, histology, systemic therapy, medical comorbidities/patient genetics, and tumor molecular features. This review will discuss the current state of brain directed radiation for brain metastasis. We will also discuss future directions to improve the precision of stereotactic radiosurgery and optimize whole brain radiation techniques to improve local tumor control and prevent cognitive decline without forming necrosis.
Integrating multi-modal imaging in radiation treatments for glioblastoma
Breen, William G. , Cao, Yue , Kim, Michelle M. , Kim, Michelle M , Aryal, Madhava P.

Neuro-Oncology | March 4, 2024 | Volume: 26 | Issue: Supplement_1 | Pages: S17-S25

10.1093/neuonc/noad187 | PMID 38437666 Get It

Abstract Advances in diagnostic and treatment technology along with rapid developments in translational research may now allow the realization of precision radiotherapy. Integration of biologically informed multimodality imaging to address the spatial and temporal heterogeneity underlying treatment resistance in glioblastoma is now possible for patient care, with evidence of safety and potential benefit. Beyond their diagnostic utility, several candidate imaging biomarkers have emerged in recent early-phase clinical trials of biologically based radiotherapy, and their definitive assessment in multicenter prospective trials is already in development. In this review, the rationale for clinical implementation of candidate advanced magnetic resonance imaging and positron emission tomography imaging biomarkers to guide personalized radiotherapy, the current landscape, and future directions for integrating imaging biomarkers into radiotherapy for glioblastoma are summarized. Moving forward, response-adaptive radiotherapy using biologically informed imaging biomarkers to address emerging treatment resistance in rational combination with novel systemic therapies may ultimately permit improvements in glioblastoma outcomes and true individualization of patient care.